FDAnews
www.fdanews.com/articles/81613-celldex-buys-lorantis-alteris

CELLDEX BUYS LORANTIS, ALTERIS

October 12, 2005

Celldex Therapeutics said on Wednesday it has acquired all the issued and outstanding shares of the British biotechnology company Lorantis, as well as the assets of Alteris Therapeutics. Medarex, an antibody-focused biotechnology company located in Princeton, New Jersey, will own approximately 60 percent of Celldex when the two acquisitions close. "The acquisition of Lorantis and the assets of Alteris bring important resources that we believe are complementary to Celldex's technology and that have the potential to enhance and broaden Celldex's development pipeline," said Celldex CEO Michael W. Fanger.

Red Herring (http://www.redherring.com/Article.aspx?a=13962&hed=Celldex%2BBuys%2BLorantis%2C%2BAlteris)